Vera Therapeutics Inc
VERA
Company Profile
Business description
Vera Therapeutics Inc is a clinical stage biotechnology company. It is focused on developing and commercializing transformative treatments for patients with serious immunological diseases. The company's product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection once weekly that blocks both B lymphocyte stimulator and a proliferation-inducing ligand, which stimulate B cells and plasma cells to produce autoantibodies contributing to certain autoimmune diseases.
Contact
2000 Sierra Point Parkway
Suite 1200
BrisbaneCA94005
USAT: +1 650 770-0077
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
339
Stocks News & Analysis
stocks
OpenAI is going public as the worst value among its peers
Investors are paying a steep price relative to the underlying business quality, PitchBook research says.
stocks
Wide moat healthcare leader remains undervalued
ASX healthcare giant expected to see uptick in demand from emerging markets.
stocks
This US AI winner has been unstoppable. Is it time to sell?
Astonishing results have driven this AI stock into significantly overvalued territory.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,855.90 | 79.60 | -0.89% |
| CAC 40 | 8,284.06 | 39.77 | 0.48% |
| DAX 40 | 24,991.43 | 46.48 | 0.19% |
| Dow JONES (US) | 51,561.93 | 874.86 | 1.73% |
| FTSE 100 | 10,399.70 | 39.38 | 0.38% |
| HKSE | 24,961.95 | 291.45 | -1.15% |
| NASDAQ | 26,830.96 | 23.02 | -0.09% |
| Nikkei 225 | 66,588.12 | 882.57 | -1.31% |
| NZX 50 Index | 13,161.97 | 60.36 | 0.46% |
| S&P 500 | 7,584.31 | 30.63 | 0.41% |
| S&P/ASX 200 | 8,625.10 | 80.00 | -0.92% |
| SSE Composite Index | 4,027.74 | 30.04 | -0.74% |